[Pregnancy and XXXX ].

@entity1 @entity548 @entity117 @entity21715 @entity204 @entity715
OBJECTIVE: To evaluate the management and outcome of pregnancy in @entity1 with @entity21715 . @entity1 AND METHODS: We conducted a retrospective study including all the pregnant @entity1 with @entity21715 followed between January 2000 and January 2008 in a University Hospital (h  pital Jeanne-de-Flandre, Lille, France). We report our experience of 18 pregnancies in 13 @entity1 . The management and the complications of these pregnancies were reported. RESULTS: All the @entity1 were treated with low dose @entity117 during the pregnancy. We observed one intrauterine @entity204 , one premature delivery at 29  weeks of gestation and six maternal @entity548 at delivery (33%). DISCUSSION AND CONCLUSION: It is essential to treat these @entity1 with low dose @entity117 as soon as the pregnancy begins. @entity117 will be continued in postpartum with anticoagulant treatment. This management appears to improve the obstetric outcome and decrease the @entity715 usually described. A national register seems to be necessary to evaluate the complications occurring during pregnancy and the optimum follow-up.
